Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INDP with free AI briefings, catalyst countdowns, and dilution alerts.

INDP · Indaptus Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$30.6M Cash on Hand
54.6mo Cash Runway
Follow INDP by email Get an email when INDP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INDP, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
TLR Agonist Decoy20 Solid Tumor, Adult Phase 1/2 · NCT05651022 Active not recruiting

Also used in these trials (approved or third-party drugs, not INDP's own candidates): Tislelizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INDP holds $30.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.7M/quarter from operations, an estimated runway of 54.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INDP files for a raise →

👥 Who Owns INDP

Insiders 60.3% Other 5%+ holders 8% Institutions (18 holders) 0.5% Public and other holders 31.2%
HolderTypeShares% of sharesAs of
Yun Yao
10% owner
Insider 41,991,000 27.34% 2026-10-16
SINO LION VENTURES Ltd
10% owner
Insider 38,895,000 25.32% 2026-10-16
Junyi Dai
Chief Executive Officer
Insider 11,250,000 7.32% 2026-10-16
Yang Ting 5%+ holder (13D) 9,948,173 6.48% 2026-10-16
Lazar David E. 5%+ holder (13D) 2,064,000 1.34% 2026-03-23
Jeffery A. Meckler 5%+ holder (13D) 273,103 0.18% 2025-12-22
Jeffrey A Meckler
Co-Chief Executive Officer, Director · +235,861 options
Insider 229,929 0.15% 2025-12-22
Michael James Newman
CSO and Director, Director · +75,000 options
Insider 101,074 0.07% 2025-12-22
Walt Addison Linscott
Chief Operating Officer · +75,000 options
Insider 54,426 0.04% 2025-12-22
Nir Sassi
Chief Financial Officer · +75,000 options
Insider 26,758 0.02% 2025-12-22
Avraham Ben-Tzvi
Director · +25,000 options
Insider 25,100 0.02% 2025-12-23
Matthew Charles McMurdo
Director
Insider 25,000 0.02% 2026-02-26

Share count 153,602,583 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full INDP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INDP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.